Cetuximab, an epidermal growth factor receptor (EGFR)-targeting antibody, remains the only Food and Drug Administration-approved targeted therapy for squamous cell carcinoma (SCC) of head and neck/esophagus. However, in clinical trials, cetuximab only benefited a subset of patients and frequently caused toxicity. Predicting which patients respond to cetuximab remains unsolved. The authors sought to identify predictive biomarkers in EGFR signaling and autophagy pathways, which may be impacted by cetuximab under certain treatment conditions.
Methods:
In vitro responses of SCC cell lines to cetuximab under various nutrient conditions were assessed by WST-8 growth assay. Functional profiles of several EGFR signaling biomarkers were investigated by Luminex-based assays and corroborated with immunoblots. Autophagy markers were analyzed with immunoblots.
Results:
In vitro growth response assays identified cetuximab responder and nonresponder cell lines. Optimal growth conditions and growth factors enhanced responses, and even reversed nonresponsiveness in some cell lines. Strong correlation was found between response in growth assays (reference assay) and dynamic changes in p-Erk1/2 and LC3-II (index assays).
Conclusions:
This study indicates that nutrient modification may enhance cetuximab response in SCC patients. Biomarker results strengthen the hypothesis that dynamic biomarkers can be used to predict patient response to cetuximab. Future studies are warranted to test in more complex samples including patient-derived tumor tissues.
FerlayJ, ColombetM, SoerjomataramI, et al.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019; 144:1941.
2.
BrayF, FerlayJ, SoerjomataramI, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394. Erratum in: CA Cancer J Clin, 2020l;70:313.
3.
SiegelRL, MillerKD, FuchsHE, et al.Cancer Statistics, 2021. CA Cancer J Clin, 2021; 71:7.
4.
ZanoniDK, MonteroPH, MigliacciJC, et al.Survival outcomes after treatment of cancer of the oral cavity (1985–2015). Oral Oncol, 2019; 90:115.
5.
ChaturvediAK, EngelsEA, PfeifferRM, et al.Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol, 2011; 29:4294.
6.
AlsahafiE, BeggK, AmelioI, et al.Clinical update on head and neck cancer: Molecular biology and ongoing challenges. Cell Death Dis, 2019; 10:540.
7.
BonnerJA, HarariPM, GiraltJ, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 2006; 354:567.
8.
VermorkenJB, MesiaR, RiveraF, et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008; 359:1116.
9.
VermorkenJB, TrigoJ, HittR, et al.Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol, 2007; 25:2171.
10.
BibaultJE, MorelleM, PerrierL, et al.Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer. Cancer Radiother, 2016; 20:357.
11.
SchragD, DueckAC, NaughtonMJ, et al.Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. J Clin Oncol, 2015; 33:6504.
12.
EconomopoulouP, PerisanidisC, GiotakisEI, et al.The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): Anti-tumor immunity and clinical applications. Ann Transl Med, 2016; 4:173.
13.
FerrisRL, BlumenscheinGJr, FayetteJ, et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med, 2016; 375:1856.
14.
SeiwertTY, BurtnessB, MehraR, et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol, 2016; 17:956.
15.
SalehK, EidR, HaddadFG, et al.New developments in the management of head and neck cancer - impact of pembrolizumab. Ther Clin Risk Manag, 2018; 14:295.
16.
QinY, ZhengX, GaoW, et al.Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma. Mol Ther Oncolytics, 2021; 20:342.
17.
VogelsteinB, PapadopoulosN, VelculescuVE, et al.Cancer genome landscapes. Science, 2013; 339:1546.
18.
WheelerDL, DunnEF, HarariPM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol, 2010; 7:493.
19.
SuhY, AmelioI, Guerrero UrbanoT, et al.Clinical update on cancer: Molecular oncology of head and neck cancer. Cell Death Dis, 2014; 5:e1018.
20.
BraigF, KriegsM, VoigtlaenderM, et al.Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism. Cancer Res, 2017; 77:1188.
21.
MarretG, BiècheI, DupainC, et al.Genomic alterations in head and neck squamous cell carcinoma: Level of evidence according to ESMO scale for clinical actionability of molecular targets (ESCAT). JCO Precision Oncol, 2021; 5:215.
22.
Viloria-PetitA, CrombetT, JothyS, et al.Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res, 2001; 61:5090.
23.
NiuG, SunX, CaoQ, et al.Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res, 2010; 16:2095.
24.
SwickAD, PrabakaranPJ, MillerMC, et al.Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. Mol Cancer Ther, 2017; 16:1257.
25.
MahalBA, CatalanoPJ, HaddadRI, et al.Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States. Cancer Epidemiol Biomarkers Prev, 2019; 28:1660.
26.
CramerJD, BurtnessB, LeQT, et al.The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol, 2019; 16:669.
27.
LiX, LuY, PanT, et al.Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy, 2010; 6:1066.
28.
YadavG, LiuN. Trends in protein separation and analysis—the advance of stain-free technology. Bioradiations 2014;1. www.bioradiations.com/trends-in-protein-separation-and-analysis-the-advance-of-stain-free-technology/
29.
ZhangZ, SinghR, AschnerM. Methods for detection of autophagy in mammalian cells. Curr Protoc Toxicol 2017;69:20.12.1.
30.
ComerJE, ChopraAK, PetersonJW, et al.Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect Immun, 2005; 73:8275.
31.
SakaiK, AraoT, ShimoyamaT, et al.Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. FASEB J, 2006; 20:311.
32.
MatsuoT, NishizukaSS, IshidaK, et al.Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models. BMC Res Notes, 2011; 4:140.
33.
WoolstonC, MartinS. Analysis of tumor and endothelial cell viability and survival using sulforhodamine B and clonogenic assays. Methods Mol Biol, 2011; 740:45.
34.
TominagaH, IshiyamaM, OhsetoF, et al.A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun, 1999; 36:47.
35.
BrunnerD, FrankJ, ApplH, et al.Serum-free cell culture: The serum-free media interactive online database. ALTEX, 2010; 27:53.
NgM, CunninghamD. Cetuximab (Erbitux)—an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract, 2004; 58:970.
38.
EngelmanRW, OwensUE, BradleyWG, et al.Mammary and submandibular gland epidermal growth factor expression is reduced by calorie restriction. Cancer Res, 1995; 55:1289.
39.
SadeghianM, RahmaniS, KhalesiS, et al.A review of fasting effects on the response of cancer to chemotherapy. Clin Nutr, 2021; 40:1669.
40.
SafdieFM, DorffT, QuinnD, et al.Fasting and cancer treatment in humans: A case series report. Aging (Albany NY), 2009; 1:988.
41.
BetiolJ, VillaLL, SicheroL. Impact of HPV infection on the development of head and neck cancer. Braz J Med Biol Res, 2013; 46:217.
42.
MaddaloM, BorghettiP, TomasiniD, et al.Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for locally advanced head and neck cancer: Long-term survival and toxicity outcomes of a randomized phase 2 trial. Int J Radiat Oncol Biol Phys, 2020; 107:469.
43.
VermorkenJB, PsyrriA, MesíaR, et al.Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: Retrospective analysis of the phase III EXTREME trial. Ann Oncol, 2014; 25:801.
44.
AngKK, BerkeyBA, TuX, et al.Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res, 2002; 62:7350.
45.
JedlinskiA, AnsellA, JohanssonAC, et al.EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. J Oral Pathol Med, 2013; 42:26.
46.
AgulnikM, da Cunha SantosG, HedleyD, et al.Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol, 2007; 25:2184.
47.
LeelahavanichkulK, AmornphimolthamP, MolinoloAA, et al.A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol, 2014; 8:105.
48.
EgloffAM, GrandisJ. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets, 2006; 10:639.
49.
YoshidaT, OkamotoI, OkabeT, et al.Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer, 2008; 122:1530.
50.
LiS, SchmitzKR, JeffreyPD, et al.Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 2005; 7:301.
51.
ChiariniF, EvangelistiC, McCubreyJA, et al.Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci, 2015; 36:124.
52.
SwickA, TanJX, FowlerT, et al.Induction of autophagy as a mechanism of therapeutic resistance in head and neck cancer. Cancer Res, 2016; 76:2129.
53.
LeiY, KansyBA, LiJ, et al.EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex. Oncogene, 2016; 35:4698.
54.
LeeY-S, EckersJC, KimpleRJ, Chapter 13 -Autophagy in head and neck cancer therapy. In: Kimple RJ (ed.), Cancer Sensitizing Agents for Chemotherapy, Improving the Therapeutic Ratio in Head and Neck Cancer. Cambridge, MA: Academic Press,, 2020; 6:281.
55.
SinghSS, VatsS, ChiaAY, et al.Dual role of autophagy in hallmarks of cancer. Oncogene, 2018; 37:1142.
56.
PatilS, RaoRS, RajAT. Dual Role of Autophagy in Oral Cancer. J Int Oral Health, 2015; 7:i.
57.
MizushimaN, YoshimoriT. How to interpret LC3 immunoblotting. Autophagy, 2007; 3:542.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
